Navigation Links
New study validates longevity pathway
Date:3/7/2013

A new study demonstrates what researchers consider conclusive evidence that the red wine compound resveratrol directly activates a protein that promotes health and longevity in animal models. What's more, the researchers have uncovered the molecular mechanism for this interaction, and show that a class of more potent drugs currently in clinical trials act in a similar fashion. Pharmaceutical compounds similar to resveratrol may potentially treat and prevent diseases related to aging in people, the authors contend.

These findings are published in the March 8 issue of Science.

For the last decade, the science of aging has increasingly focused on sirtuins, a group of genes that are believed to protect many organisms, including mammals, against diseases of aging. Mounting evidence has demonstrated that resveratrol, a compound found in the skin of grapes as well as in peanuts and berries, increases the activity of a specific sirtuin,SIRT1, that protects the body from diseases by revving up the mitochondria, a kind of cellular battery that slowly runs down as we age. By recharging the batteries, SIRT1 can have profound effects on health.

Mice on resveratrol have twice the endurance and are relatively immune from effects of obesity and aging. In experiments with yeast, nematodes, bees, flies and mice, lifespan has been extended.

"In the history of pharmaceuticals, there has never been a drug that binds to a protein to make it run faster in the way that resveratrol activates SIRT1," said David Sinclair, Harvard Medical School professor of genetics and senior author on the paper. "Almost all drugs either slow or block them."

In 2006, Sinclair's group published a study showing that resveratrol could extend the lifespan of mice, and the company Sirtris Pharmaceuticals, which was started by HMS researchers, was founded to make drugs more potent than resveratrol. (Sinclair is a co-founder of Sirtris, a GlaxoSmithKline co
'/>"/>

Contact: David Cameron
david_cameron@hms.harvard.edu
617-432-0441
Harvard Medical School
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
2. iLab Solutions Conducts Its Third Annual Core Facility Benchmarking Study
3. University of Colorado Cancer Center Study Shows the Preferred Feeding Method is not the Medically Best in Malnourished Pediatric Cancer Patients
4. University of Colorado Cancer Center Study Shows That Problem-Solving Training Helps Mothers Cope with Child’s Cancer Diagnosis
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. New Study Shows Impressive Results with Abutment-Free Sophono System
8. EU Study Finds UK Health Product Benefit Metric Flawed
9. Notre Dame study explores the potential benefits and threats of nanotechnology research
10. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
11. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... highlights for the three and six month ... experienced a strong second quarter with the ... therapy treatment in,refractory head and neck cancer ...
... DIEGO, July 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter 2008,financial results after the NASDAQ Global Market ... Jack Lief, Arena,s President and Chief,Executive Officer, and ... Financial Officer, will host a conference call at ...
... Abt Associates has been,ranked 19th in the Marketing News ... Research firms. The listing is based on 2007 revenue ... for,calendar 2007 was $55.1 million. Total company revenues for ... Abt Associates market research activities are carried out ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 9Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 10Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 11Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 12Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 13Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 14Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 15Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 16Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 17Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 18Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 19Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 20Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 21Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 22Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 23Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 24Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 25Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 26Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 27Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 28Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 29Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 30Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 31Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 32Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 33Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 3Abt Associates Ranked One of Top 20 U.S. Market Research Firms 2
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... Medical Branch at Galveston are the first to ... cervical cancer should begin colorectal cancer screening earlier ... finding a high incidence of secondary colorectal cancers ... new recommendations that the younger women in this ... after their initial cervical cancer diagnosis instead of ...
(Date:4/17/2014)... View of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a ... deep history that most of us take for granted. ... in many spots around the globe shifted from hunting ... and plants. , It seems so straightforward and yet ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... one of the most important prerequisites for a positive self ... rather than the exception that children and young people are ... or subject to bullying are particularly critical of their appearance ... long period. This is revealed in a new thesis in ...
... Prevention (CDC) today released new infection control recommendations ... (KPC)-Producing Organisms, one of the most ... that infections with these highly resistant bacteria are ... In Guidance for Control of Infections with Carbapenem-Resistant ...
... the media. A new study by Dr. Yaniv Levyatan ... of Israel,s National Security College, describes how our side ... "Information warfare" plays a crucial role in ... conventional weapons. Therefore, the information warfare against terrorist organizations ...
Cached Biology News:Children who are dissatisfied with their appearance often have problems with their peer group 2Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms 2Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: